Modified IGF-1 analog with reduced binding to IGFBPs; extended half-life vs native IGF-1. Research chemical.
Recombinant IGF-1 with an N-terminal 13-amino-acid extension and Arg3 substitution that markedly reduces IGFBP binding, extending circulating half-life.
Evidence summary in progress. See the citations section below for the underlying research papers.
No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.
No documented drug interactions on file.
Not FDA approved. Sold as a research chemical for cell-culture use.
Not available via 503A/503B compounding pharmacies.
Regulatory data last verified 4/19/2026
No indexed ClinicalTrials.gov studies for IGF-1 LR3. This usually means the compound isn't being studied under an IND — check the citations section for peer-reviewed research instead.